Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | -2.94% | -55.30% | +27.74% |
Sales 2024 * | 83.23M 6.95B | Sales 2025 * | 72.48M 6.05B | Capitalization | 134M 11.2B |
---|---|---|---|---|---|
Net income 2024 * | -48M -4.01B | Net income 2025 * | -52M -4.34B | EV / Sales 2024 * | 1.61 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.85 x |
P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
-3.99
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -2.94% | ||
1 week | -55.30% | ||
Current month | +21.47% | ||
1 month | -5.71% | ||
3 months | +30.26% | ||
6 months | +69.23% | ||
Current year | +27.74% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 01/10/01 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 02/21/02 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 20/18/20 |
Elaine Jones
BRD | Director/Board Member | 69 | 01/14/01 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 01/10/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
10/24/10 | 1.98 | -2.94% | 12,154,821 |
09/24/09 | 2.04 | -51.31% | 41,562,499 |
08/24/08 | 4.19 | +2.95% | 40,523,342 |
07/24/07 | 4.07 | -6.86% | 4,440,551 |
06/24/06 | 4.37 | -1.35% | 5,076,011 |
Delayed Quote Nasdaq, May 11, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.74% | 134M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CTMX Stock